Literature DB >> 2346538

Relative bioavailability of three cefixime formulations.

F Kees1, K G Naber, G Sigl, W Ungethüm, H Grobecker.   

Abstract

Three galenic formulations of cefixime (tablet, syrup and dry suspension) containing 200 mg each were compared with respect to their relative bioavailability in twelve healthy volunteers. All three formulations showed reliable absorption. Mean peak plasma concentrations were reached after 3.3-3.5 h, mean terminal half lives were 2.9-3.1 h. 18-24% of the dose administered were recovered unchanged in the urine. Best bioavailability was obtained with the dry suspension (AUC0-infinity = 25.8 +/- 7.0 micrograms/ml h; Cmax = 3.4 +/- 0.9 microgram/ml), followed by the tablet (AUC0-infinity = 20.9 +/- 8.1 micrograms/ml h; Cmax = 3.0 +/- 1.0 micrograms/ml) and the syrup which is based on triglycerides (AUC0-infinity = 17.8 +/- 5.9 micrograms/ml h; Cmax = 2.4 +/- 0.7 micrograms/ml). The statistical analysis resulted in bioinequivalence between dry suspension and syrup. It is concluded that best bioavailability of cefixime after oral administration is guaranteed when taken in an "aqueous medium" either as dry suspension or as tablet with "plenty of liquid".

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2346538

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  [Pharmacokinetics of cefixime in volunteers and a literature comparison with the new ester prodrug cephalosporins].

Authors:  F Kees; K G Naber
Journal:  Infection       Date:  1990       Impact factor: 3.553

2.  Cefixime absorption kinetics after oral administration to humans.

Authors:  X D Liu; L Xie; J P Gao; L S Lai; G Q Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Apr-Jun       Impact factor: 2.441

3.  Biliary excretion of cefixime: assessment in patients provided with T-tube drainage.

Authors:  J F Westphal; F Jehl; M Schloegel; H Monteil; J M Brogard
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.